Skip to main content

Diabetes, Type 2 News (Page 5)

Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2

FDA Approves Susvimo for Diabetic Macular Edema

WEDNESDAY, Feb. 5, 2025 -- The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only FDA-approved treatment ...

Micronutrient Deficiencies Seen in More Than 45 Percent With Type 2 Diabetes

THURSDAY, Jan. 30, 2025 – More than 45 percent of patients with type 2 diabetes (T2D) have micronutrient deficiencies, with the most prevalent deficiency being vitamin D, according to a...

GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment

THURSDAY, Jan. 30, 2025 – The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of...

Benefits of Pediatric Obesity Treatment Endure Into Young Adulthood

TUESDAY, Jan. 28, 2025 – A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to a study published online Jan. 21 in JAMA Pediatrics....

Vitamin Deficiencies Common in Type 2 Diabetes

WEDNESDAY, Jan. 29, 2025 – “Hidden hunger” – low levels of essential vitamins or minerals – is common among people with type 2 diabetes, a new evidence review says Overall, as many as 45% of type 2...

Fasting Glucose, Age, Male Sex, BMI All Linked to Diabetes Development

WEDNESDAY, Jan. 29, 2025 – Fasting plasma glucose (FPG), age, body mass index (BMI), and male sex are all associated with development of diabetes, according to a study published online Jan. 23 in...

FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients

WEDNESDAY, Jan. 29, 2025 – A popular diabetes drug just got a major new approval – and it could be a game-changer for millions of Americans at risk for kidney failure. The U.S. Food and Drug...

FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease

PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease worsening,...

Heart Health Risk Factors Continue To Increase

TUESDAY, Jan. 28, 2025 – Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, according to an annual report from the American Heart...

Patients With Diabetes Have Comparable Health Expenses After RYGB or Sleeve Gastrectomy

TUESDAY, Jan. 28, 2025 – For patients with diabetes undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), overall expenditures decrease in the postsurgical period, with no...

Weight Loss Boosts Long-Term Health of Kids With Obesity

TUESDAY, Jan. 28, 2025 – Helping kids with obesity drop pounds can have a huge impact on their future health. When these children and teens lose weight, they are less likely to have type 2 diabetes,...

Weight Loss Boosts Long-Term Health of Kids With Obesity

TUESDAY, Jan. 28, 2025 – Helping kids with obesity drop pounds can have a huge impact on their future health. When these children and teens lose weight, they are less likely to have type 2 diabetes,...

Diabetes Remission Increased With Dapagliflozin Plus Calorie Restriction

MONDAY, Jan. 27, 2025 – For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated with a significantly higher rate of remission of...

Certain Meds and Diet Can Reverse Type 2 Diabetes

FRIDAY, Jan. 24, 2025 – People can reverse their type 2 diabetes through a combination of calorie cutting and medication, a small clinical trial says. Overweight and obese adults caused their...

Several Factors Play Role in Semaglutide Initiation for Obesity Without Diabetes

THURSDAY, Jan. 23, 2025 – Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Diabetes Mellitus

Related drug support groups

metformin, Ozempic, Victoza, Mounjaro, Lantus, semaglutide, Trulicity, glipizide, Rybelsus, view more... Farxiga, Jardiance, Lantus Solostar, Humalog, Novolog, liraglutide, Janumet, insulin glargine, tirzepatide, Januvia, insulin lispro, Bydureon, Tresiba, Levemir, dulaglutide, Glucophage, Invokana, insulin degludec, Humulin N